Life Sciences Strategy Summit on IP & Exclusivity 2023

Reviewing the first UPC caselaw, SPC updates, the BOA plausibility decision and Regulatory Exclusivity Strategies. Join this leading community of life science IP professionals and build a comprehensive patent prosecution strategy within Europe and further

JOIN US THERE
Munich, Germany
9-11 October, 2023

“A great forum to gain and exchange expert knowledge on aspects of IP, Regulatory and business law that determine market exclusivity”

Margaret O’Gara, Director of Intellectual Property, Nanobiotix

WHY ATTEND

The Life Science Strategy Summit on IP & Exclusivity is returning to Munich this October. The premier life science IP event, we're gathering the leading legal professionals working in biopharma for 3 days practical discussion on practical and industry-led patent strategy, patent prosecution and market exclusivity topics.

The first meeting following the launch of the Unified Patent Court (UPC), join the leading community of life science patent professionals to understand the industry’s reaction to the new court system and have candid discussions with the European life science intellectual property experts.

New for 2023 - The Global SPC & PTE Forum 2023

Join this one-day event and understand the key legislative changes and case law regarding SPC and PTE protection in Europe and beyond.

HIGHLIGHTS INCLUDE

  1. Cross-industry end-user panel discussing the opening of the UPC and the life science industry response with Chr. Hansen and IFF alongside a judicial perspective with 4 legal judges and 3 technical judges. 
  2. IP Minds Roundtable discussions on: Antibody Case Law, Biosimilar IP Considerations, Arrow Declaration, Clinical Trials and Patent Strategy, AI and Life Science Patents, Trade Secrets vs Patent Protection, FTO: Best Practices
  3. 1-day dedicated event on SPCs entitled: Global SPC & PTE Forum 2023 with speakers from the European Commission, a Pan-European Patent Office Panel, the EPO, MSD, Polpharma Group and Adalvo
  4. Build a practical Exclusivity Strategy and understand the upcoming changes from the European Commission with speakers from Venable, Alkermes, Pieris Pharmaceuticals, BioNTech and Adalvo

SPC AND PTE FORUM 2023 (9TH OCTOBER)

Supplementary Protection Certificate's (SPCs) and Patent Term Extensions (PTEs) are a fundamental way in which European law compensates biopharmaceutical companies for their loss in exclusivity rights over a 20-year patent period. This exclusive event workshop will bring together the leading in-house counsel, private practitioners

Discover the latest trends and case studies within European SPC law and understand how this will affect your IP strategy and regulators to discuss the leading trends within SPC/PTE trends from filing to litigation.

PART 1

  • Discover the latest trends and case studies within European SPC law and understand how this will affect your IP strategy

PART 2

  • Understand the proposed changes to SPCs under the new UPC system and analyse whether a unitary SPC can be utilised

PART 3

  • Learn from a wider discussion of PTE extension trends in USA, China, South Korea and Japan

AUDIENCE BREAKDOWN

50%
Pharma, Biotech, Medical Devices companies
40%
Law Firms
10%
Vendors

Pharma, Biotech, Medical Devices companies

Law Firms

Vendors

FIND OUT MORE ABOUT THIS YEARS SUMMIT ON OUR NEW AGENDA

We're excited to be returning to Munich this year to review the latest Regulatory Exclusivity Strategies and legal challenges for pharmaceutical, biotech & medical device companies.

Fill out this short form to view the full 2023 agenda and find out more about how to get invovled

 

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick above.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.


ACCESS THE AGENDA HERE

LIFE SCIENCES STRATEGY SUMMIT 2023 COMMUNITY

From our advisory board and speakering faculty to our media and strategic partners, our series wouldn't be possible without the contributions of Our esteemed community of in-house IP counsel, private practice and regulatory leaders. 

2023 SPEAKERS

 

Toni Santamaria

VP Intellectual Property
Adalvo Ltd

Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.  

Toni Santamaria

VP Intellectual Property
Adalvo Ltd

Toni Santamaria

VP Intellectual Property
Adalvo Ltd

Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.  

 

Gemma Campabadal

Director Patent Law
Johnson and Johnson

Gemma Campabadal

Director Patent Law
Johnson and Johnson

Gemma Campabadal

Director Patent Law
Johnson and Johnson
 

Ina Burck

Director Intellectual Property
BioNTech

Ina Burck

Director Intellectual Property
BioNTech

Ina Burck

Director Intellectual Property
BioNTech
 

John Kirkland

Executive Director, Intellectual Property and Litigation Counsel
Litigation Counsel Alkermes

John Kirkland

Executive Director, Intellectual Property and Litigation Counsel
Litigation Counsel Alkermes

John Kirkland

Executive Director, Intellectual Property and Litigation Counsel
Litigation Counsel Alkermes
 

Thomas Boehmer

Head of Intellectual Property
Pieris Pharmaceuticals

Thomas Boehmer

Head of Intellectual Property
Pieris Pharmaceuticals

Thomas Boehmer

Head of Intellectual Property
Pieris Pharmaceuticals
 

Cecile Teles

Head Patent Attorney
Zentiva

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

Cecile Teles

Head Patent Attorney
Zentiva

Cecile Teles

Head Patent Attorney
Zentiva

Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.

Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.

Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.

Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.

 

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz is currently Head of the IP Legal Practice at Insud Pharma Group, a diversified biopharmaceutical business based in Madrid, Spain, that she joined in 2017. Beatriz holds a degree in Law and a Master Degree in Intellectual Property by the University of Alicante (Magister Lvcentinvs). Before joining Insud Pharma, Beatriz worked in private practice as a patent litigator in Madrid with Bird & Bird where she specialized on pharma patent litigation.

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz Díaz de Escauriaza

Head of IP Legal
Insud Pharma

Beatriz is currently Head of the IP Legal Practice at Insud Pharma Group, a diversified biopharmaceutical business based in Madrid, Spain, that she joined in 2017. Beatriz holds a degree in Law and a Master Degree in Intellectual Property by the University of Alicante (Magister Lvcentinvs). Before joining Insud Pharma, Beatriz worked in private practice as a patent litigator in Madrid with Bird & Bird where she specialized on pharma patent litigation. During her years at Bird&Bird she also intervened before the European authorities, having also acted before the European Court of Justice at Strasbourg.

 

Jiri Slavik

Senior Manager Intellectual Property
Adalvo

Jiri Slavik

Senior Manager Intellectual Property
Adalvo

Jiri Slavik

Senior Manager Intellectual Property
Adalvo
 

Kora Knuchel

Chief IP and Legal Officer (CIPLO)
Biognosys AG

Kora Knuchel

Chief IP and Legal Officer (CIPLO)
Biognosys AG

Kora Knuchel

Chief IP and Legal Officer (CIPLO)
Biognosys AG
 

Bea Mcdonald

Head of IP
Vaccitech

Bea Mcdonald

Head of IP
Vaccitech

Bea Mcdonald

Head of IP
Vaccitech
 

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

 

James Hogan

Assistant Managing Counsel
MSD

James Hogan

Assistant Managing Counsel
MSD

James Hogan

Assistant Managing Counsel
MSD
 

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

 

Kit Carter

Head of IP Litigation
Sandoz

Kit Carter

Head of IP Litigation
Sandoz

Kit Carter

Head of IP Litigation
Sandoz
 

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr.

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong

Partner, Advisory Board Member
Venable, Centre for Biosimilars

Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.

Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.

 

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France.

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

 

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann has been heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 30 FTE since then. She has been the Senior Vice President since 2012. Her focus is on generics, branded products, clinical nutrition and medical devices. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and has been a European Patent Attorney since 2006. She holds a Dr. rer. nat.

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann has been heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 30 FTE since then. She has been the Senior Vice President since 2012. Her focus is on generics, branded products, clinical nutrition and medical devices. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and has been a European Patent Attorney since 2006. She holds a Dr. rer. nat. from the University of Jena and a diploma in chemistry from the University of Frankfurt.

 

Paul Inman

Partner
Gowling

With 20 years' experience of litigating intellectual property disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which has included acting on high-profile pharmaceutical patent infringement and revocation actions in the UK Patents Court.

Paul Inman

Partner
Gowling

Paul Inman

Partner
Gowling

With 20 years' experience of litigating intellectual property disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which has included acting on high-profile pharmaceutical patent infringement and revocation actions in the UK Patents Court.

As a global industry, life science businesses expect commercial advice from lawyers with an international outlook. Paul's specialist experience and skill set make him perfectly placed to provide this expertise and client care.

His role has extended to litigating across industries as diverse as fashion, oil drilling and consumer products both here, and overseas.

Whether "success" is measured by getting the right court order at the end of the dispute, or evaluating and reaching the right commercial settlement between the parties beforehand, a thorough and balanced assessment on each case is critical. The ultimate aim for Paul is to provide his clients with well-rounded advice and guidance to ensure the best possible outcome.

His interest and expertise in the life sciences sector has also seen him advising on regulatory work concerning European pharmaceutical bodies.

Paul's role gives him the unique opportunity to act for a wide range of patent and design proprietors, which he relishes.

Paul's first degree is in molecular biology and biochemistry, which means he can take on highly complex pharmaceutical or biotechnology inventions, as easily as less technical (but equally important) mechanical patents and designs.

Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 20 years of litigation in cases leading to more than 40 reported judgments, ranging from the tribunals of the UK Patent Office (UKIPO) up to the House of Lords (UK Supreme Court), European Patent Office (EPO) and European Court of Justice (CJ EU).

As well as litigating in the English courts, Paul has co-ordinated and advised on IP and regulatory litigation matters across the globe, as far afield as the US, South Africa, Malaysia, the Philippines, Australia and New Zealand, and closer to home, in Scotland, Ireland, France, Germany, Holland, Denmark, Belgium, Spain, Portugal, Italy and Greece.

It is this great variety of work and clients that, for Paul, really makes the job dynamic and exciting, week-in and week-out.

 

Rian Kalden

Honourable Judge
UPC Court of Appeal

Rian Kalden

Honourable Judge
UPC Court of Appeal

Rian Kalden

Honourable Judge
UPC Court of Appeal
 

Matthias Zigann

Honourable Judge
UPC Local Division, Munich

Matthias Zigann

Honourable Judge
UPC Local Division, Munich

Matthias Zigann

Honourable Judge
UPC Local Division, Munich
 

Dr Oliver Werner

Head Patent Department, Head SPC Working Group
German Patent and Trade Mark Office

Dr Oliver Werner

Head Patent Department, Head SPC Working Group
German Patent and Trade Mark Office

Dr Oliver Werner

Head Patent Department, Head SPC Working Group
German Patent and Trade Mark Office
 

Dr Martijn de Lange

Patent Examiner
Netherlands Patent Office

Dr Martijn de Lange

Patent Examiner
Netherlands Patent Office

Dr Martijn de Lange

Patent Examiner
Netherlands Patent Office
 

Roberto Romandini

Legal Member of the Board of Appeal
EPO

Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich.  Since 2019 he has been a legal member at the Boards of Appeal at the EPO. 

Roberto Romandini

Legal Member of the Board of Appeal
EPO

Roberto Romandini

Legal Member of the Board of Appeal
EPO

Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich.  Since 2019 he has been a legal member at the Boards of Appeal at the EPO. 

 

Tobias Pichlmaier

Honourable Judge
UPC Local Division, Munich

Tobias Pichlmaier

Honourable Judge
UPC Local Division, Munich

Tobias Pichlmaier

Honourable Judge
UPC Local Division, Munich
 

Ronny Thomas

Honourable Judge
UPC Local Division, Dusseldorf

Ronny Thomas

Honourable Judge
UPC Local Division, Dusseldorf

Ronny Thomas

Honourable Judge
UPC Local Division, Dusseldorf
 

Dolores Cassidy

Head of Patent/SPC Examination
Intellectual Property Office of Ireland

Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry.  In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs).  In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.

Dolores Cassidy

Head of Patent/SPC Examination
Intellectual Property Office of Ireland

Dolores Cassidy

Head of Patent/SPC Examination
Intellectual Property Office of Ireland

Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry.  In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs).  In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.

 

Lena Pauschenwein

Legal Officer
DG Grow | European Commission

Lena PAUSCHENWEIN, Legal Officer, Directorate-General GROW - Internal Market, Industry, Entrepreneurship and SMEs, European Commission, Brussels, Belgium

Lena Pauschenwein is a jurist specialised in intellectual property law and works in the Intangible Economy Unit of the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) of the European Commission.

Lena Pauschenwein

Legal Officer
DG Grow | European Commission

Lena Pauschenwein

Legal Officer
DG Grow | European Commission

Lena PAUSCHENWEIN, Legal Officer, Directorate-General GROW - Internal Market, Industry, Entrepreneurship and SMEs, European Commission, Brussels, Belgium

Lena Pauschenwein is a jurist specialised in intellectual property law and works in the Intangible Economy Unit of the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) of the European Commission.

Lena holds law degrees from the University of Vienna (Magister iuris) and the University of Glasgow (LLM), both with a focus on intellectual property and technology law. Prior to joining the European Commission in 2021, she worked at the Austrian Supervisory Authority for Collective Management Organisations.

 

Martin Schmidt

Life Science Technical Judge
UPC

Martin Schmidt

Life Science Technical Judge
UPC

Martin Schmidt

Life Science Technical Judge
UPC
 

Rainer Friedrich

Director of Global IP and Biotech Technical Judge
CSL Behring and the UPC

Rainer Friedrich

Director of Global IP and Biotech Technical Judge
CSL Behring and the UPC

Rainer Friedrich

Director of Global IP and Biotech Technical Judge
CSL Behring and the UPC

LIFE SCIENCES PATENT ADVISORY BOARD

Author:

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

Intellectual Property Counsel
iff

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel (Director)
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel (Director)
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Author:

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Author:

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

Alexandra Moulson

VP Development
Polpharma Biologics

Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.

She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.

Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.

Author:

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech

Author:

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Author:

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

2023 PARTNERS

PLATINUM PARTNERS

GOLD PARTNERS

ASSOCIATE MEDIA PARTNER

MEDIA PARTNERS

BOOK YOUR PLACE TODAY

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase after

— June 30, 2023 —

Monday, April 24, 2023 to Friday, June 30, 2023
Tier 1 - In-House
€699
Super Super Early Bird Pricing - Register before 30th June to save €600
You can add our pre-event workshop as an add-on during registration
Monday, April 24, 2023 to Friday, June 30, 2023
Tier 2 - Law Firms
€1399
Super Super Early Bird Pricing - Register before 30th June to save €600
You can add our pre-event workshop as an add-on during registration
Monday, April 24, 2023 to Friday, June 30, 2023
Tier 3 - Service Providers/Vendors
€1799
Super Super Early Bird Pricing - Register before 30th June to save €600
Wednesday, April 26, 2023 to Thursday, October 12, 2023
SPC & PTE Forum - PRE DAY ONLY
€799
Preparing registration...

Partner with Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us